Elevated glypican-1 expression is associated with an unfavorable prognosis in pancreatic ductal adenocarcinoma

Haizhen Lu\textsuperscript{1,\textasteriskcentered}, Fangfei Niu\textsuperscript{2,\textasteriskcentered}, Fang Liu\textsuperscript{2}, Jiajia Gao\textsuperscript{2}, Yulin Sun\textsuperscript{2} & Xiaohang Zhao\textsuperscript{2} \textsuperscript{\textasteriskcentered}

\textsuperscript{1}Department of Pathology, National Cancer Center/Cancer Hospital, Chinese Academy of Medical Science & Peking Union Medical College, Beijing 100021, China
\textsuperscript{2}State Key Laboratory of Molecular Oncology, National Cancer Center/Cancer Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing 100021, China

\textsuperscript{\textasteriskcentered}These authors contributed equally.

Abstract

Pancreatic ductal adenocarcinoma (PDAC) is the most lethal cancer in humans, with a 5-year survival rate of <5\%. Recently, glypican-1 (GPC1)-expressing circulating exosomes were found to be a promising diagnostic tool for PDAC. However, the aberrant expression of GPC1 has not been systematically evaluated in large-scale clinical samples of PDAC. Here, we performed a comprehensive analysis of GPC1 mRNA and protein expression features. Included in this study were 178 PDAC patients from the cancer genome atlas (TCGA) and 186 subjects whose tissues were used in immunohistochemical staining assays. We demonstrated that GPC1 mRNA was silenced in normal pancreata; however, it was re-expressed in PDAC tissues probably because of the promoter hypomethylation. The GPC1 protein was barely expressed in the normal and adjacent non-cancerous pancreata. In tumor tissues, 59.7\% (111/186) of the detected samples showed positive expression. Notably, GPC1 was elevated in 63.6\% (34/55) of early stage cases. High levels of GPC1 were associated with poorer differentiation and larger tumor diameters. Kaplan–Meier analysis showed a significant difference in overall survival between the groups categorized by GPC1 expression ($P = 0.0028$). Multivariate analyses indicated that GPC1 was a significant risk factor for poor overall survival with a 1.82-fold increase in the hazard ratio ($P = 0.0022$). In conclusion, during pancreatic tumorigenesis, GPC1 was ectopically expressed and served as an independent poor prognostic factor. Our findings highlighted the alluring prospect of GPC1 as an early diagnostic and prognostic marker as well as a therapeutic target for PDAC.

Introduction

Pancreatic cancer is the most lethal cancer in humans worldwide. Although its incidence is ranked 15th among common malignancies [1], only approximately 4\% of patients live 5 years after diagnosis [2]. Notably, due to the asymptomatic nature of early-stage pancreatic cancer, approximately 80–85\% of cases at initial diagnosis present with unresectable advanced or metastatic disease. The median survival time for these patients is only 3–14 months [2]. Therefore, screening or early detection of pancreatic cancer is a promising tool to improve clinical outcome.
Today, carbohydrate antigen 19-9 (CA 19-9) is a commonly utilized tumor marker in the diagnosis and monitoring of pancreatic ductal adenocarcinoma (PDAC), the most common form of pancreatic neoplasm. It is mainly synthesized by normal pancreatic and biliary ductal cells and, to a lesser extent, by gastric, colonic, endometrial, and salivary epithelia [3]. Approximately 10% of Caucasian and 22% of non-Caucasian population do not express CA 19-9 due to the lack of the fucosyltransferase needed for CA 19-9 production [3, 4]. In 16% of PDAC cases, CA19-9 was elevated 2–3 years prior to diagnosis, with sensitivity increasing toward diagnosis [5]. In early-stage (stage I and II) pancreatic cancer, up to 66% of patients had an elevated CA19-9 level at diagnosis [4], and the diagnostic sensitivity and specificity were 55–75% and 56–81%, respectively [6]. Overall, CA 19-9 is neither a very sensitive nor specific marker for resectable or local PDAC. Therefore, identifying novel serum markers that could aid in the detection of early-stage PDAC remains a clear unmet need.

Recently, it was shown that glypican-1-expressing (GPC1+) circulating exosomes (crExos) can be used to detect early-stage PDAC and gain insights into disease progression and tumor burden [7, 8]. GPC1+ crExos levels were significantly elevated in patients with histologically confirmed pancreatic cancer precursor lesions and PDAC compared with those in patients with benign pancreatic disease and healthy controls. Importantly, GPC1+ crExos showed a nearly 100% sensitivity and specificity even for early stage PDAC, indicating its outstanding potential for early detection of the disease [7].

GPC1 is a heparan sulfate proteoglycan (HSPG) that binds to the external surface of the plasma membrane by a glycosyl-phosphatidylinositol (GPI) anchor [9, 10]. The human genome includes six glypicans (GPC1 to GPC6), and GPC1 is relatively closely related to GPC2 with approximately 37% amino-acid identity. Under physiological conditions, GPC1 is expressed predominantly in the brain, skin, skeletal muscle, kidney and testis, but there is little or no expression in the liver, lung, pancreas and blood cells during development [11]. In PDAC, it was reported that GPC1 was significantly overexpressed at both the mRNA and protein levels [12, 13]. Moreover, increased GPC1 was associated with perineural invasion and poor prognosis of PDAC based on limited samples [13]. However, the aberrant expression of GPC1 and its clinical significance in PDAC have not been evaluated in large-scale clinical samples. In this study, we analyzed the mRNA and protein expression characteristics of GPC1 in PDAC using the RNA sequencing dataset from the cancer genome atlas (TCGA) and by immunohistochemical staining assays.

Materials and Methods

TCGA RNA sequencing data mining

The RNA sequencing data from 178 patients with pancreatic adenocarcinoma were obtained from TCGA (https://tcga-data.nci.nih.gov). The subjects included eight pancreatic neuroendocrine carcinoma patients, four pancreatic mucinous noncystic carcinoma patients, and 13 patients with an unknown pathological type; the remaining patients were ductal (n = 137) or another type of (n = 16) pancreatic adenocarcinoma. The final cohort used in this study excluded the eight patients with pancreatic neuroendocrine carcinoma because these cases originated from the endocrine portion of the pancreas. Among the 170 enrolled patients, 157 cases had detailed clinical information. The median duration of patient follow-up was 13 months. The expression of GPC1 mRNA and its clinical significance were analyzed in these patients.

Tissue microarrays

Four tissue microarrays of pancreatic adenocarcinoma were purchased from Shanghai Outdo Biotech Co., Ltd (Shanghai, China). Among them, three tissue microarrays from 174 patients had recorded follow-up information. The median duration of patient follow-up was 10.5 months (range 1–87 months). The other tissue microarray contained two normal pancreata, four cases of chronic pancreatitis, 13 pairs of malignant tumors and their matched adjacent noncancerous tissues, four metastatic tumors of the liver and abdominal wall, and eight positive metastatic lymph nodes.

Immunohistochemistry

The tissue microarrays were deparaffinized and rehydrated at room temperature, and they were then immersed in methanol containing 0.3% hydrogen peroxide for 10 min to block endogenous peroxidase. Heat-induced antigen retrieval was performed in a water bath for 30 min in a pH 6.0 antigen retrieval solution. After washing, the sections were incubated overnight with anti-GPC1 antibody (1:200, Cat No. GTX104557; GeneTex Inc., Irvine, CA) at 4°C. The staining was performed using the Prolink-2 Plus HRP rabbit polymer detection kit (Golden Bridge International Inc., Bothell, WA) according to the manufacturer’s instructions. The images were captured using Aperio ScanScope CS software (Vista, CA).

The results were evaluated separately by two independent pathologists. The GPC1 staining intensity and area were quantified as described previously [14]. Briefly, the GPC1 staining area was scored as follows: (1) 0, <5% of
the epithelial cells in the respective lesions; (2) 1, 5–25% of the epithelial cells; (3) 2, 26–50% of the epithelial cells; (4) 3, 51–75% of the epithelial cells; and (5) 4, ≥75% of the epithelial cells. The intensity was graded as follows: (1) 0, negative; (2) 1+, weak (yellow); (3) 2+, moderate (light brown); and (4) 3+, strong (dark brown). A final score between 0 and 12 was achieved by multiplication of the extent of positivity and intensity. A staining index was used in which ≤1 was considered negative, 2–3 was weak, 4–7 was moderate, and ≥8 was considered strong expression.

Statistical analysis

The Mann–Whitney U test or Kruskal–Wallis test was used to compare the read per million (RPM) values between two or multiple groups. In addition, the RPM value correlation matrix of six members from the glypican family was calculated by Spearman’s rank correlation and visualized using the ggplot2 package in R (https://www.r-project.org/). The chi-square test was used to compare qualitative data. The Kaplan–Meier method was used to determine the relationship between the levels of GPC1 and patient survival, and log-rank analysis was performed to compare survival curves. Univariate and multivariate analyses were performed using the Cox regression model. P < 0.05 was considered significant. All analyses were performed using SPSS, version 19.0 (IBM software Inc., Chicago, IL).

Results

As the predominantly expressed glypican in pancreatic cancer, GPC1 mRNA is associated with worse tumor biological characteristics

According to the TCGA RNA sequencing data from pancreatic adenocarcinoma patients (n = 178), we observed that GPC1 is the major expressed form in pancreatic adenocarcinoma among the six glypican family members in the human genome (GPC1-6; Fig. 1A). Meanwhile, GPC1 levels were negatively correlated with those of GPC3 and GPC5 and, positively correlated with GPC2 (Spearman’s rank correlation; Fig. 1B). Notably, the expression of glypicans is relatively tissue/cell-specific based on the genome-wide annotation of the tissue specificity of the human transcriptome (Fig. 1C), while normal pancreata barely express glypicans [15]. Accordingly, GPC1 was re-expressed in pancreatic carcinogenesis. Promoter hypomethylation may be substantially responsible for the re-expression of the GPC1 gene because the methylation status of GPC1 was inversely moderately correlated with its mRNA levels in pancreatic tumor tissues (Pearson correlation coefficient = −0.5176; P < 0.0001; Fig. 2A).

We divided the patients with PDAC into three groups, with high, moderate and low GPC1 expression levels, using two tertiles of RPM values of GPC1 in tumor tissues. Kaplan–Meier survival analysis with a log-rank test showed that there was no correlation between GPC1 mRNA levels and overall survival (Fig. 2B). However, moderate and high expression levels of GPC1 were significantly associated with a shorter relapse time (P = 0.0240; Fig. 2C).

The correlations between the clinicopathological characteristics of PDAC patients and GPC1 mRNA expression in their tumors were also compared (Fig. 2D). The patients with alcoholic drinking habits, chronic pancreatitis, and poor pathological differentiation tended to express high levels of GPC1 (Mann–Whitney U tests, all of P < 0.05). Thus, it seems that GPC1 was ectopically expressed during tumorigenesis, and increased expression of GPC1 mRNA was associated with PDAC recurrence.

GPC1 protein is absent in the exocrine portion of normal pancreata but is significantly overexpressed in PDAC

To confirm the aberrant expression of GPC1 at the transcriptional level, an immunohistochemistry assay was performed in normal pancreata (n = 2), chronic pancreatitis (n = 4), non-tumor pancreata tissues (n = 169), PDAC (n = 186), metastases (n = 4) and metastatic lymph nodes (n = 7). GPC1 was undetectable in the normal pancreata (Fig. 3A). Most of the chronic pancreatitis cases still lacked GPC1 expression (Fig. 3B). In the adjacent noncancerous tissues, GPC1 staining remained barely detected (Fig. 3C), and only one specimen showed weak expression of GPC1 (0.6%, 1/169). Positive cytoplasmic and membrane immunostaining for GPC1 was observed in 59.7% (111/186) of the PDAC tumors (Table S1), 100% (4/4) of the liver or abdominal wall metastases, and 85.7% (6/7) of the metastatic lymph nodes (Fig. 3D–F). In the positively stained PDAC tissues, 57 (51.4%) had weak, 39 (35.1%) had moderate, and 15 (13.5%) had strong staining of GPC1 (Fig. 4A–C). Importantly, 35 of 55 cases (63.6%) with early-stage PDAC (stage 1) showed positive staining of GPC1. In these 35 subjects, 57, 31.4% and 11.4% showed weak, moderate and strong expression, respectively. Therefore, GPC1 is dramatically overexpressed in the PDAC and metastatic tissues compared with normal and benign pancreatic tissues, even in early-stage patients (all P < 0.0001; Fig. 4D).

The correlations between the clinicopathological characteristics and GPC1 expression were subsequently analyzed (Table 1). Higher GPC1 levels were associated with being male (P = 0.0186) and with worse tumor biological features, including poor pathological differentiation (P = 0.0005) and larger tumor sizes (P = 0.0331). However,
Figure 1. Gene expression of glypican family members in various tissues. (A) GPC1 is the most strongly expressed glypicans in human PDAC tissues (n = 178) according to the TCGA RNA sequencing data. (B) The correlation matrix plot of six glypicans in PDAC tissues. Spearman’s rank correlation coefficients were calculated and are shown in each square. (C) The tissue-specific expression of glypican family members according to the normalized RNA-sequencing data downloaded from the Human Protein Atlas portal (www.proteinatlas.org). The normal pancreas tissues are highlighted by red arrows.
there was no correlation between GPC1 protein and tumor invasion depth, lymph node metastasis, and American Joint Committee on Cancer (AJCC) staging.

Prognostic relevance of GPC1 protein

Kaplan–Meier survival analysis indicated a significant correlation between positive GPC1 staining and a shorter overall survival time in the PDAC patients \((P = 0.0028; \text{Fig. 4E})\). The median survival time of the positive and negative expression groups was 10 and 20.5 months, respectively.

These findings were confirmed by both univariate and multivariate Cox regression analyses (Table 2). In the univariate analysis, the GPC1-positive patients exhibited a 1.77-fold increase in the hazard ratio (HR) for overall survival.
survival compared with the GPC1 negative group \((P = 0.0028)\). The other significant risk factors included lymph node metastasis \((P = 0.0019)\), distant metastasis \((P = 0.0200)\) and AJCC staging \((P = 0.0004)\). In the multivariate analysis, GPC1 expression \((HR = 1.82, P = 0.0022)\) and AJCC staging \((HR = 2.24, P = 0.0002)\) were independent prognostic factors for mortality.

**Discussion**

In general, the expression of glypican is regulated in a developmental stage- and tissue-specific manner. However, in this study, we observed abnormal expression of GPC1 mRNA and protein in pancreatic cancers, in agreement with previous reports \([12, 13]\). One of the most important findings in this study is the observation that promoter hypomethylation is responsible for the re-expression of the GPC1 gene to a great extent. Based on the TCGA samples \((n = 178)\), hypomethylation could moderately explain its overexpression, with an R-squared value of 0.2679. In addition, gene amplification may also result in its aberrant expression. Although the amplification event was observed in only one case among the TCGA samples \((1/185)\), the GPC1 gene amplification rate reached 11\% \((12/109)\) in another whole-exome sequencing sample set with PDAC \([16]\). This result suggests that promoter hypomethylation and gene amplification of GPC1 are frequent in PDAC.

In addition, we found that GPC1 expression was associated with worse biological behaviors of PDAC, such as poorer differentiation and larger tumor diameters, indicating that aberrantly expressed GPC1 may play important roles in tumorigenesis. Previous studies had shown that GPC1 strengthened the mitogenic responses of PDAC cells to fibroblast growth factor 2 (FGF2), heparin binding EGF-like growth factor (HB-EGF), and hepatocyte growth factor (HGF) as a growth factor coreceptor \([12, 17, 18]\). It also enhanced the deleterious actions of TGF-\(\beta\) in pancreatic cancer cells \([19, 20]\). Accordingly, GPC1 is crucial for efficient growth, metastasis, and angiogenesis in cancer cells and genetic mouse models of PDAC \([21, 22]\). Therefore, it is understandable that GPC1 is an
independent unfavorable prognostic factor for PDAC. Furthermore, at the mRNA level, we found that GPC1 was higher in patients with a chronic pancreatitis background and drinking habits, indicating that inflammation-related risk factors may facilitate the expression of GPC1 in PDAC. We suspect that the clinical significance of GPC1 is not entirely consistent at the mRNA and protein levels due to the different specimens used and the differential abundance between mRNA and protein. In addition, PDAC is one of the most stroma-rich cancers [23]. The heterogeneous stroma is composed of various cellular and extracellular components, including mesenchymal cells, extracellular matrix (ECM), and soluble proteins. Therefore, a correlation analysis of GPC1 mRNA and protein levels needs to be performed with the same batch of microdissected tissue specimens to exclude the influence of ECM and stromal components.

During early neurogenesis, GPC1 determines brain size and the differentiation of neural stem cells by regulating FGF and canonical Wnt signaling [24–26]. In commissural neurons, GPC1 is required as a coreceptor for the Sonic Hedgehog (Shh)-dependent induction of its own receptor to mediate commissural axon guidance [27]. GPC1 could also act as a negative regulator of Shh signaling in biliary development, and downregulation of GPC1 led to developmental biliary defects and biliary atresia [28]. In bone, GPC1 regulates bone morphogenetic protein 2 (BMP2)-mediated osteogenesis [29]. In endothelial cells, GPC1 induces metaphase arrest and centrosome overproduction, and it mediates flow-induced NO synthase (eNOS) activation to protect endothelial function [30–32]. Because of the essential roles of GPC1 in the pathways of heparin binding growth factors and the TGF-β families, Wnt and Shh, it appears that GPC1 participates in the carcinogenesis...
of several tumors. Except for PDAC, the overexpression of GPC1 has been observed in the tumor tissues of gliomas, ameloblastomas, prostate cancer and esophageal squamous cell carcinoma (ESCC) [7, 33–37]. However, contradictory results were observed in colorectal cancer and breast cancer [38–41]. In ESCC, high levels of GPC1 were also significantly associated with chemoresistance to cisplatin [33].

Importantly, GPC1 was regarded as a more promising biomarker for PDAC. In tissues, our study and previous

### Table 1. The expression of GPC1 protein and its clinical significance in 186 PDAC specimens.

| Total number of patients | Glypican-1 staining |  |  |
|--------------------------|---------------------|--|--|
|  | Gender | n = 186 | Negative | Positive |  |
|  | Male | 118 | 40 (33.9) | 78 (66.1) | 0.0186 |
|  | Female | 68 | 35 (51.5) | 33 (48.5) |  |
|  | Age (year) |  |  |  |  |
|  | ≤60 | 79 | 30 (38.0) | 49 (62.0) | 0.6274 |
|  | >60 | 106 | 44 (41.5) | 62 (58.5) |  |
|  | Differentiation |  |  |  |  |
|  | I | 17 | 14 (82.4) | 3 (17.6) | 0.0005 |
|  | II | 137 | 54 (39.4) | 83 (60.6) |  |
|  | III | 22 | 5 (22.7) | 17 (77.3) |  |
|  | Tumor size (cm) |  |  |  |  |
|  | ≤6 | 160 | 70 (43.8) | 90 (56.3) | 0.0331 |
|  | >6 | 24 | 5 (20.8) | 19 (79.2) |  |
|  | Nerve invasion |  |  |  |  |
|  | No | 107 | 45 (42.1) | 62 (57.9) | 0.5749 |
|  | Yes | 79 | 30 (38.0) | 49 (62.0) |  |
|  | Tumor depth |  |  |  |  |
|  | T1, T2 | 107 | 41 (38.3) | 66 (61.7) | 0.1705 |
|  | T3, T4 | 61 | 30 (49.2) | 31 (50.8) |  |
|  | Lymph node metastasis |  |  |  |  |
|  | N0 | 102 | 41 (40.2) | 61 (59.8) | 0.5595 |
|  | N1 | 74 | 33 (44.6) | 41 (55.4) |  |
|  | Distant organs metastasis |  |  |  |  |
|  | M0 | 178 | 71 (39.9) | 107 (60.1) | 0.5684 |
|  | M1 | 8 | 4 (50.0) | 4 (50.0) |  |
|  | AJCC staging |  |  |  |  |
|  | Stage 1 | 55 | 20 (36.4) | 35 (63.6) | 0.3032 |
|  | Stage 2, 3, 4 | 121 | 54 (44.6) | 67 (55.4) |  |

Chi-square test was used.

### Table 2. Univariate and multivariate survival analysis of GPC1 expression for overall survival in 186 patients with PDAC.

|  | Hazard ratio (95% CI) |  |  |
|--------------------------|---------------------|--|--|
|  | Univariate |  |  |  |
|  | Gender (female vs. male) | 0.81 (0.57–1.17) | 0.2639 |
|  | Age (>60 vs. ≤60 years old) | 1.23 (0.87–1.74) | 0.2468 |
|  | Differentiation (Poorly vs. moderately vs. well) | 1.41 (0.94–2.13) | 0.0987 |
|  | Tumor size (>6 cm vs. ≤6 cm) | 1.16 (0.70–1.94) | 0.5624 |
|  | Nerve invasion (yes vs. no) | 1.08 (0.76–1.53) | 0.6706 |
|  | Tumor invasive depth (T4 + T3 vs. T1 + T2) | 1.25 (0.85–1.83) | 0.2584 |
|  | Lymph node metastasis (N1b, c+N2 vs. N0 + N1a) | 1.78 (1.24–2.56) | 0.0019 |
|  | Distant organs metastasis (M1 vs. M0) | 2.70 (1.17–6.10) | 0.0200 |
|  | AJCC staging (IV + III + II vs. I) | 2.15 (1.40–3.29) | 0.0004 |
|  | Glypican-1 expression (positive vs. negative) | 1.77 (1.22–2.57) | 0.0028 |
|  | Multivariate |  |  |  |
|  | AJCC staging (IV + III + II vs. I) | 2.24 (1.47–3.43) | 0.0002 |
|  | Glypican-1 expression (positive vs. negative) | 1.82 (1.24–2.67) | 0.0022 |

© 2017 The Authors. Cancer Medicine published by John Wiley & Sons Ltd.
studies showed that GPC1 was dramatically overexpressed in malignant cells [12, 13]. In serum, circulating GPC1 showed a similar diagnostic performance to CA19-9; however, the sensitivity and specificity of GPC1+ crExos were greater than those of soluble GPC1. Notably, GPC1+ crExos was a near perfect classifier in distinguishing patients with PDAC from healthy donors and patients with benign pancreatic disease, even for early-stage PDAC [7]. Moreover, compared with levels in breast cancer patients, GPC1+ crExos was higher in PDAC patients. Notably, for either mRNA or protein, our results revealed that the increase in GPC1 in malignant cells was independent of AJCC stage, suggesting that it is an excellent candidate for early-stage PDAC. It seems that GPC1-based measurement will aid in early diagnosis and provide more opportunities for curative surgical therapy for PDAC patients. Therefore, our results further support the notion that GPC1 is an attractive diagnostic and prognostic biomarker for detecting early stages of pancreatic cancer.

In summary, we investigated the mRNA and protein expression features of GPC1 in large-scale clinical samples of PDAC. The results demonstrated that the GPC1 gene was re-expressed in PDAC mainly due to promoter hypomethylation, even for early-stage PDAC. High levels of GPC1 were associated with poorer pathological differentiation and worse biological behaviors. GPC1 could serve as an independent unfavorable prognostic factor in PDAC. Further studies in a larger cohort will be required for unequivocal validation of its clinical application, especially for very early stages of the disease. However, given the oncogenic roles of GPC1, GPC1 is indeed a powerful diagnostic and prognostic marker as well as a promising therapeutic target for PDAC.

Acknowledgments

This work was supported by grants from the National Natural Science Foundation (81572840, 81572365, 81372591 and 91629105), the State Key Project for Basic Research (2014CBA02001 and 2014CBA02002) of China and the CAMS Innovation Fund for Medical Sciences (2016-I2M-1-001).

Conflict of Interest

The authors have no conflicts of interest to declare.

References

1. Torre, L. A., F. Bray, R. L. Siegel, J. Ferlay, J. Lortet-Tieulent, and A. Jemal. 2015. Global cancer statistics, 2012. CA Cancer J. Clin. 65:87–108.
2. Vincent, A., J. Herman, R. Schulick, R. H. Hruban, and M. Goggins. 2011. Pancreatic cancer. Lancet 378:607–620.
3. Scara, S., P. Bottoni, and R. Scatena. 2015. CA 19-9: biochemical and clinical aspects. Adv. Exp. Med. Biol. 867:247–260.
4. Bergquist, J. R., C. A. Puig, C. R. Shubert, R. T. Groeschl, E. B. Habermann, M. L. Kendrick, et al. 2016. Carbohydrate antigen 19-9 elevation in anatomically resectable, early stage pancreatic cancer is independently associated with decreased overall survival and an indication for neoadjuvant therapy: a national cancer database study. J. Am. Coll. Surg. 223:52–65.
5. O’Brien, D. P., N. S. Sandanayake, C. Jenkinson, A. Gentry-Maharaj, S. Apostolidou, E. O. Fourkala, et al. 2015. Serum CA19-9 is significantly upregulated up to 2 years before diagnosis with pancreatic cancer: implications for early disease detection. Clin. Cancer Res. 21:622–631.
6. Chan, A., I. Prassas, A. Dimitromanolakis, S. Serra, E. P. Diamandis, and I. M. Blasutig. 2014. Validation of biomarkers that complement CA19.9 in detecting early pancreatic cancer. Clin. Cancer Res. 20:5787–5795.
7. Melo, S. A., L. B. Luecke, C. Kahler, A. F. Fernandez, S. T. Gammon, J. Kaye, et al. 2015. Glypican-1 identifies cancer exosomes and detects early pancreatic cancer. Nature 523:177–182.
8. Weber, C. 2015. Biomarkers: the challenge to find biomarkers for the early detection of pancreatic cancer. Nat. Rev. Gastroenterol. Hepatol. 12:427.
9. Filmus, J., and S. B. Selleck. 2001. Glypicans: proteoglycans with a surprise. J Clin Invest. 108:497–501.
10. Filmus, J., M. Capurro, and J. Rast. 2008. Glypicans. Genome Biol. 9:224.
11. Litwack, E. D., J. K. Ivins, A. Kumbasar, S. Paines-Saunders, C. S. Stipp, and A. D. Lander. 1998. Expression of the heparan sulfate proteoglycan glypican-1 in the developing rodent. Dev. Dyn. 211:72–87.
12. Kleeff, J., T. Ishiwata, A. Kumbasar, H. Friess, M. W. Buchler, A. D. Lander, and M. Korc. 1998. The cell-surface heparan sulfate proteoglycan glypican-1 regulates growth factor action in pancreatic carcinoma cells and is overexpressed in human pancreatic cancer. J Clin Invest. 102:1662–1673.
13. Duan, L., X. Q. Hu, D. Y. Feng, S. Y. Lei, and G. H. Hu. 2013. GPC-1 may serve as a predictor of perineural invasion and a prognosticator of survival in pancreatic cancer. Asian J. Surg. 36:7–12.
14. Hao, X. P., T. G. Pretlow, J. S. Rao, and T. P. Pretlow. 2001. Beta-catenin expression is altered in human colonic aberrant crypt foci. Cancer Res. 61:8085–8088.
15. Uhlen, M., L. Fagerberg, B. M. Hallstrom, C. Lindskog, P. Oksvold, A. Mardinoglu. 2015. Proteomics. Tissue-based map of the human proteome. Science 347:1260419.
16. Witkiewicz, A. K., E. A. McMillan, U. Balaji, G. Baek, W. C. Lin, J. Mansour, et al. 2015. Whole-exome sequencing of pancreatic cancer defines genetic diversity and therapeutic targets. Nat. Commun. 6:6744.

17. Kleeff, J., S. Wildi, A. Kumbasar, H. Friess, A. D. Lander, and M. Korc. 1999. Stable transfection of a glypican-1 antisense construct decreases tumorigenicity in PANC-1 pancreatic carcinoma cells. Pancreas 19:281–288.

18. Ding, K., M. Lopez-Burks, J. A. Sanchez-Duran, M. Korc, and A. D. Lander. 2005. Growth factor-induced shedding of syndecan-1 confers glypican-1 dependence on mitogenic responses of cancer cells. J. Cell Biol. 171:729–738.

19. Li, J., J. Kleeff, K. Felix, R. Penzel, M. W. Buchler, et al. 2004. Glypican-1 antisense transfection modulates TGF-beta-dependent signaling in Colo-357 pancreatic cancer cells. Biochem. Biophys. Res. Commun. 320:1148–1155.

20. Kayed, H., J. Kleeff, S. Keleg, X. Jiang, R. Penzel, T. Giese, et al. 2006. Correlation of glypican-1 expression with TGF-beta, BMP, and activin receptors in pancreatic ductal adenocarcinoma. Int. J. Oncol. 29:1139–1148.

21. Aikawa, T., C. A. Whipple, M. E. Lopez, J. Gunn, A. Young, A. D. Lander, and M. Korc. 2008. Glypican-1 modulates the angiogenic and metastatic potential of human and mouse cancer cells. J Clin Invest. 118:89–99.

22. Whipple, C. A., A. L. Young, and M. Korc. 2012. A KrasG12D-driven genetic mouse model of pancreatic cancer requires glypican-1 for efficient proliferation and angiogenesis. Oncogene 31:2535–2544.

23. Waghray, M., M. Yalamanchili, M. P. di Magliano, and D. M. Simeone. 2013. Deciphering the role of stroma in pancreatic cancer. Curr. Opin. Gastroenterol. 29:537–543.

24. Jen, Y. H., M. Musacchio, and A. D. Lander. 2009. Glypican-1 controls brain size through regulation of fibroblast growth factor signaling in early neurogenesis. Neural Dev. 4:33.

25. Shiau, C. E., N. Hu, and M. Bronner-Fraser. 2010. Altering Glypican-1 levels modulates canonical Wnt signaling during trigeminal placode development. Dev. Biol. 348:107–118.

26. Oikari, L. E., R. K. Okolicsanyi, A. Qin, C. Yu, L. R. Griffiths, and L. M. Haupt. 2016. Cell surface heparan sulfate proteoglycans as novel markers of human neural stem cell fate determination. Stem Cell Res. 16:92–104.

27. Wilson, N. H., and E. T. Stoeckli. 2013. Sonic hedgehog regulates its own receptor on postcrossing commissural axons in a glypican-1-dependent manner. Neuron 79:478–491.

28. Cui, S., M. Leyva-Vega, E. A. Tsai, S. F. EauClaire, J. T. Glessner, H. Hakomarson, et al. 2013. Evidence from human and zebrafish that GPC1 is a biliary atresia susceptibility gene. Gastroenterology 144:1107–15e3.

29. Dwivedi, P. P., R. H. Grose, J. Filmus, J. Filmus, C. S. Hii, C. J. Xian, P. J. Anderson, and B. C. Powell. 2013. Regulation of bone morphogenetic protein signalling and cranial osteogenesis by Gpc1 and Gpc3. Bone 55:367–376.

30. Qiao, D., X. Yang, K. Meyer, and A. Friedl. 2008. Glypican-1 regulates anaphase promoting complex/cyclosome substrates and cell cycle progression in endothelial cells. Mol. Biol. Cell 19:2789–2801.

31. Ebong, E. E., S. V. Lopez-Quintero, V. Rizzo, D. C. Spray, and J. M. Tarbell. 2014. Shear-induced endothelial NOS activation and remodeling via heparan sulfate, glypican-1, and syndecan-1. Integr. Biol. (Camb.) 6:338–347.

32. Zeng, Y., and J. Liu. 2016. Role of glypican-1 in endothelial NOS activation under various steady shear stress magnitudes. Exp. Cell Res. 348:184–189.

33. Hara, H., T. Takahashi, S. Serada, M. Fujimoto, T. Ohkawara, R. Nakatsuka, et al. 2016. Overexpression of glypican-1 implicates poor prognosis and their chemoresistance in oesophageal squamous cell carcinoma. Br. J. Cancer 115:66–75.

34. Truong, Q., I. O. Justiniano, A. L. Nocon, J. T. Soon, S. Wissmueller, D. H. Campbell, and B. J. Walsh. 2016. Glypican-1 as a biomarker for prostate cancer: isolation and characterization. J Cancer. 7:1002–1009.

35. Bologna-Molina, R., A. Mosqueda-Taylor, and N. Molina-Frechero. 2015. Differential expression of glypican-1 in ameloblastoma variants. Appl. Immunohistochem. Mol. Morphol. 23:153–160.

36. Suhovskikh, A. V., L. A. Mostovich, I. S. Kunin, M. M. Boboev, G. I. Nepomnyashchikh, S. V. Aidagulova, and E. V. Grigorieva. 2013. Proteoglycan expression in normal human prostate tissue and prostate cancer. ISRN Oncol. 2013:680136.

37. Su, G., K. Meyer, C. D. Nandini, D. Qiao, S. Salamat, and A. Friedl. 2006. Glypican-1 is frequently overexpressed in human gliomas and enhances FGF-2 signaling in glioma cells. Am. J. Pathol. 168:2014–2026.

38. Fernandez-Vega, I., O. Garcia-Suarez, B. Garcia, A. Crespo, A. Astudillo, and L. M. Quiros. 2015. Heparan sulfate proteoglycans undergo differential expression alterations in right sided colorectal cancer, depending on their metastatic character. BMC Cancer 15:742.

39. De Robertis, M., M. Arigoni, L. Loiacono, F. Riccardo, A. K. Witkiewicz, H. Hakonarson, et al. 2013. Evidence from human and zebrafish that GPC1 is a biliary atresia susceptibility gene. Gastroenterology 144:1107–15e3.
effects of multiple heparin-binding growth factors in breast cancer cells. Cancer Res. 61:5562–5569.
41. Fernandez-Vega, I., O. Garcia, A. Crespo, S. Castanon, P. Menendez, A. Astudillo, and L. M. Quiros. 2013. Specific genes involved in synthesis and editing of heparan sulfate proteoglycans show altered expression patterns in breast cancer. BMC Cancer 13:24.

Supporting Information

Additional supporting information may be found in the online version of this article:

Table S1. The immunohistochemical staining results of 186 PDAC specimens.